PulmoGate raises $2.1M seed
Announced 20 November 2026
◆ The Round
PulmoGate raised $2.1M in seed funding, announced on 20 November 2026, led by Beyond Next Ventures Co., Ltd., with participation from Teijin Pharma Limited, Mitsubishi UFJ Capital Co., Ltd., STATION Ai Central Japan No. 2 Investment Limited Partnership. The round is tracked live by Fusion42 as part of the Raise fund database and the Scout startup database.
◆ About PulmoGate
Medical AI startup developing AI-driven solutions for diagnosis, treatment, and rehabilitation of interstitial lung disease. PulmoGate is based in Japan and currently at seed stage, operating in Biotech.
◆ Investors
LeadBeyond Next Ventures Co., Ltd.
ParticipationTeijin Pharma Limited, Mitsubishi UFJ Capital Co., Ltd., STATION Ai Central Japan No. 2 Investment Limited Partnership
◆ Market context
This funding event is a citable node in Fusion42's market graph: it links PulmoGate's Scout profile to the funds behind the round and to related Wire analysis, and is refreshed from public announcements as the round is confirmed or extended. It is the same live market data Arthur reasons over when benchmarking a founder's own raise against what is closing in the market right now.
◆ Explore the market
◆ FAQ
How much did PulmoGate raise?
PulmoGate raised $2.1M in its seed round, announced 2026-11-20.
Who invested in PulmoGate's seed round?
The round was led by Beyond Next Ventures Co., Ltd., with participation from Teijin Pharma Limited, Mitsubishi UFJ Capital Co., Ltd. and STATION Ai Central Japan No. 2 Investment Limited Partnership.
What does PulmoGate do?
Medical AI startup developing AI-driven solutions for diagnosis, treatment, and rehabilitation of interstitial lung disease.
Verified 20 November 2026 · Sources: public filings